atrasentan has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demirakca, S; Dieckmann, R; Gebhard, MM; Gorenflo, M; Hagl, S; Herpel, E; Klimpel, H; Neumayer, S; Ullmann, MV | 1 |
| Chancellor, MB; Chermansky, CJ; Hiragata, S; Nelson, JB; Nishizawa, O; Ogawa, T; Pflug, BR; Sasatomi, K; Seki, S; Yoshimura, N | 1 |
2 other study(ies) available for atrasentan and Chronic Disease
| Article | Year |
|---|---|
Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow.
Topics: Animals; Atrasentan; Blood Pressure; Cardiac Output; Chronic Disease; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Hypertension, Pulmonary; Hypertrophy; Immunohistochemistry; Lung; Pulmonary Artery; Pulmonary Circulation; Pyrrolidines; Random Allocation; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Vascular Endothelial Growth Factor A | 2007 |
Therapeutic effects of endothelin-A receptor antagonist on bladder overactivity in rats with chronic spinal cord injury.
Topics: Animals; Atrasentan; Chronic Disease; Endothelin A Receptor Antagonists; Female; Pyrrolidines; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Urinary Bladder, Overactive | 2008 |